Alteon's Alagebrium Demonstrates Cardiovascular Activity In Recently Published Report Indicating Potential Wide-Ranging Benefits In Cardiovascular Diseases
15 févr. 2007 13h25 HE
|
Alteon Inc.
Vascular Reactivity Observed After Twice Daily Dosing
PARSIPPANY, N.J., February 15, 2007 (PRIME NEWSWIRE) -- Alteon Inc. (AMEX:ALT) announced today that data demonstrating the ability of...
Alagebrium Demonstrates Cardiovascular Activity in Recently Published Report Indicating Potential Wide-Ranging Benefits in Cardiovascular Diseases
15 févr. 2007 08h30 HE
|
Alteon Inc.
Vascular Reactivity Observed After Twice Daily Dosing
PARSIPPANY, N.J., February 15, 2007 (PRIME NEWSWIRE) -- Alteon Inc. (AMEX:ALT) announced today that data demonstrating the ability of...
Alteon Notified by AMEX of Acceptance of Plan of Compliance Regarding Continued Listing Standards
30 janv. 2007 14h38 HE
|
Alteon Inc.
PARSIPPANY, N.J., Jan. 30, 2007 (PRIME NEWSWIRE) -- Alteon Inc. (AMEX: ALT) announced today that on January 24, 2007, it received a notice from the staff (the "Staff") of the American Stock Exchange,...
Alteon Announces Receipt of $3 Million in Private Secured Convertible Debt and Warrant Financing
12 janv. 2007 10h55 HE
|
Alteon Inc.
PARSIPPANY, N.J., Jan. 12, 2007 (PRIME NEWSWIRE) -- Alteon Inc. (AMEX:ALT) announced today that it has entered into a definitive agreement with institutional investors that are experienced in the...
Alteon Notified by AMEX of Continued Listing Standards Non-Compliance; Company Expects Its Common Stock to Remain Listed While It Engages in AMEX Compliance Process
13 oct. 2006 16h35 HE
|
Alteon Inc.
PARSIPPANY, N.J., Oct. 13, 2006 (PRIMEZONE) -- Alteon Inc. (AMEX:ALT) (the "Company") announced today that on October 9, 2006, it received a notice from the staff (the "Staff") of the American Stock...
Alteon Inc. to Present at the BIO InvestorForum 2006
11 oct. 2006 14h51 HE
|
Alteon Inc.
PARSIPPANY, N.J., Oct. 11, 2006 (PRIMEZONE) -- Alteon Inc. (AMEX:ALT) announced today that Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Alteon, will present at the BIO...
Alteon's alagebrium to be Evaluated in NIH-Funded Phase 2 Clinical Study Focused on Cardiovascular Aging
27 sept. 2006 15h25 HE
|
Alteon Inc.
-- Grant Awarded to University of Texas Southwestern
Medical Center --
-- Study Design Supports Alteon's Initiative in Diastolic Heart
...
Alteon's alagebrium Indicates Protective Effect in Preclinical Diabetic Nephropathy Model
20 sept. 2006 15h03 HE
|
Alteon Inc.
-- Alagebrium appears to prevent, delay, and reverse kidney damage --
-- Study highlights biological marker associated with drug response --
PARSIPPANY, N.J., Sept. 20, 2006 (PRIMEZONE) --...